Investor profile
Kester Capital
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Kester Capital is a sector-focused private equity firm that targets primary buyouts in two verticals: Technology and Life Sciences. Within Technology, the firm backs B2B software businesses with compelling horizontal or vertical applications, providers of business-critical subscription data and information, and technology-enabled B2B services businesses operating in high-growth markets with scalable models. Within Life Sciences, Kester focuses on outsourced services, products and technology providers to pharma, biotech and medtech customers — businesses with strong scientific, regulatory and technical expertise critical to their customers' compliant operations. Kester partners with ambitious management teams to help scale businesses and achieve category leadership, targeting equity investments of up to £75 million. The firm describes itself as more than a financial investor, emphasising transparency, integrity and teamwork as the foundation for long-term value creation. Since inception, Kester has delivered four consecutive exits over 4x and eight consecutive exits over 3x, and its latest vehicle, Kester Capital Fund IV, closed at its £425 million hard cap in November 2025.
Notable quotes
“We are thrilled to announce the close of Fund IV at our hard cap of £425 million. To have secured such strong support is a testament to our investment strategy, the quality of our team and the excellent results we have delivered for our investors. We greatly value the trust and support of both our long-standing and new investors.”
“Fund IV gives us the opportunity to continue to invest in our team and platform and to partner with the highest potential Technology and Life Sciences businesses. Our deep sector expertise and track record of driving value creation are more relevant than ever in today's market.”
“Having closed the new fund, we are now actively looking for new investment opportunities as well as expanding our investment team. We see significant potential in the UK lower mid-market where fundamentally attractive businesses can achieve a level of growth that bucks the wider market trend, and in turn require an investment partner like us to fulfil their ambitions.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Nutritics | Buyout | — | 2026-01 |
| Addresscloud | Buyout | — | 2025-09 |
| Re-flow | Buyout | — | 2025-03 |
| Evestia Clinical | Carve-out / Buyout | — | 2024-12 |
| The Boundary | MBO | — | 2024-07 |
| DC Byte | Buyout | — | — |
| Optibrium | Buyout | — | — |
| VIXIO | Buyout | — | — |
| Kintiga (formerly MAP Group) | Buyout | — | — |
| GXP Engaged | Buyout | — | — |
Fit check
Is Kester Capital a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit